Market Place
Sourcing Support
Novo Nordisk turns RNA attention to cardio disease in new pact
17 Jul 2023 //
FIERCE BIOTECH
Novo Nordisk Completes Acquisition of Dicerna Pharmaceuticals
28 Dec 2021 //
BUSINESSWIRE
HSR Act Waiting Period Expires for Novo Nordisk Tender Offer to Acquire Dicerna
25 Dec 2021 //
BUSINESSWIRE
Ampio Pharmaceuticals CEO passes baton to a new board member; & more
24 Nov 2021 //
ENDPTS
Novartis weighs Alnylam buy with Roche stake sale cash: report
19 Nov 2021 //
FIERCEPHARMA
Novo Nordisk bets big on RNAi, paying $3.3B to buy Dicerna
19 Nov 2021 //
FIERCEBIOTECH
Dicerna Presents Data From Phase 1 Trial of Belcesiran at AASLD 2021
12 Nov 2021 //
BUSINESSWIRE
Dicerna Announces Q3 2021 Financial Results, Provides Business Update
09 Nov 2021 //
BUSINESSWIRE
Dicerna Presents PHYOX™2 and Primary Hyperoxaluria HealthcareData at ASH
04 Nov 2021 //
BUSINESSWIRE
Dicerna flops efficacy endpoint on nedosiran in PH2
20 Oct 2021 //
FIERCEBIOTECH
Dicerna Announces Results for PHYOX 4, in Primary Hyperoxaluria Type 3
19 Oct 2021 //
BUSINESSWIRE
Dicerna Announces Poster Presentations at (AASLD) The Liver Meeting®
14 Oct 2021 //
BUSINESSWIRE
Dicerna Initiates Phase 1 Trial of DCR-AUD for Alcohol Use Disorder
28 Sep 2021 //
BUSINESSWIRE
Dicerna Announces New Executive Leadership Appointments
22 Sep 2021 //
BUSINESSWIRE
Dicerna to Participate in 16th Annual Citi Biopharma Conference
02 Sep 2021 //
BUSINESSWIRE
Dicerna wants partner to sell nedosiran
10 Aug 2021 //
FIERCEBIOTECH
Dicerna Announces Second Quarter 2021 Financial Results
09 Aug 2021 //
BUSINESSWIRE
Dicerna drops after mixed data on rival to Alnylam drug
06 Aug 2021 //
FIERCEBIOTECH
Dicerna Reports Top-Line Results From PHYOXâ„¢2 Pivotal Trial of Nedosiran
05 Aug 2021 //
BUSINESSWIRE
Dicerna`s RNAi drug shows `inconsistent` results in rare kidney disease
05 Aug 2021 //
ENDPTS
Dicerna to Report Second Quarter 2021 Financial Results on Aug. 9, 2021
02 Aug 2021 //
BUSINESS WIRE
Dicerna Announces FDA Clearance of Investigational New Drug (IND) Application
29 Jul 2021 //
BUSINESSWIRE
Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran
21 Jul 2021 //
BUSINESSWIRE
Dicerna’s RNAi drug curbs harmful protein in rare liver disease
21 Jul 2021 //
FIERCEBIOTECH
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Jul 2021 //
BUSINESSWIRE
Dicerna Starts Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran
22 Jun 2021 //
BUSINESSWIRE
Dicerna Announces Dosing Completion in Nedosiran PHYOX™4 Clinical Trial
16 Jun 2021 //
BUSINESSWIRE
Dicerna Announces Dosing Completion in Nedosiran PHYOX 4 Clinical Trial
16 Jun 2021 //
BUSINESSWIRE
Dicerna Announces FDA Acceptance of Lilly’s (IND) Application for LY3819469
27 May 2021 //
PRESS RELEASE
Dicerna Announces Boehringer Ingelheim’s Acceptance of Candidate for Development
24 May 2021 //
DICERNA
Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty for Up to $240M
08 Apr 2021 //
BUSINESSWIRE
Dicerna to Present New GalXC-Plus™ Nonclinical CNS Data at Oligonucleotide
24 Mar 2021 //
BUSINESSWIRE
Dicerna to Host Webinar on DCR-AUD Alcohol Use Disorder Candidate on March 18
10 Mar 2021 //
BUSINESSWIRE
Dicerna Announces Roche’s Initiation of GalXC™ RNAi Candidate RG6346
04 Mar 2021 //
BUSINESSWIRE
Dicerna Announces Roche’s Initiation of GalXC™ RNAi Candidate RG6346 in Pha2
03 Mar 2021 //
BUSINESSWIRE
Dicerna Initiates PHYOX™4 Trial of Nedosiran for Primary Hyperoxaluria Type 3
11 Feb 2021 //
BUSINESSWIRE
Dicerna Announces Enrollment Completion of PHYOX™2 Pivotal Trial of Nedosiran
04 Jan 2021 //
BUSINESSWIRE
Dicerna Announces Novo Nordisk’s Nomination of Candidate for Devp Under RNAi
04 Jan 2021 //
BUSINESSWIRE
Dicerna Announces Positive Updated Data From Phase 1 Trial of RG6346
16 Nov 2020 //
DICERNA
Dicerna Announces Ph1 Data on RG6346 Inv Treatment for Chronic Hepatitis B
02 Nov 2020 //
BUSINESSWIRE
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Nov 2020 //
BUSINESSWIRE
Dicerna’s nedosiran achieves urinary oxalate normalisation in PH trial
23 Oct 2020 //
CLINICALTRAILSARENA
Dicerna Presents Positive New Interim Data From PHYOX™3 Long-Term
22 Oct 2020 //
BUSINESSWIRE
Dicerna to Present Nedosiran Data at American Society of Nephrology (ASN)
09 Oct 2020 //
BIOSPACE
Dicerna to Present Nedosiran Data at American Society of Nephrology (ASN)
09 Oct 2020 //
BUSINESSWIRE
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Oct 2020 //
BUSINESSWIRE
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Sep 2020 //
BUSINESSWIRE
Dicerna Announces Positive Clinical Data for Investigational Treatments RG6346
05 Aug 2020 //
BUSINESSWIRE
Dicerna Gets Rare Pediatric Disease Designation From FDA for Nedosiran
18 Jun 2020 //
BUSINESS WIRE
Dicerna nabs speedy review voucher for leading RNAi drug
18 Jun 2020 //
FIERCE BIOTECH
Dicerna to Participate in Jefferies Virtual Global Healthcare Conference
26 May 2020 //
BUSINESSWIRE
Dicerna Announces Appointment of Douglas Pagán as Chief Financial Officer
07 May 2020 //
BUSINESSWIRE
Sofinnova Telethon Fund backs Naldini`s gene therapy; ORIC prices $75M IPO
20 Apr 2020 //
COM
Dicerna Provides Initial Observations From PHYOX™3 Trial of Nedosiran
31 Mar 2020 //
BUSINESSWIRE
Dicerna Receives ODD From USFDA DCR-A1AT for Treatment of Alpha-1 Antitrypsin
18 Mar 2020 //
BUSINESSWIRE
Dicerna™ Appoints Stephen Doberstein, Ph.D., to Board of Directors
10 Feb 2020 //
BUSINESSWIRE
Dicerna™ Appoints Stephen Doberstein, Ph.D., to Board of Directors
10 Feb 2020 //
BUSINESSWIRE
